FDA grants Galderma's nemolizumab breakthrough therapy designation
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Galdermacompany(http:// announcedthat the U.SFDA(http://has granted the company the development of the "first-in-class" IL-31 receptor alpha monoclonal antibody nemolizumab breakthrough therapy identified for the treatment of nodule itchAbout Nemolizumab
Nemolizumab is a "first-in-class" monoclonal antibody that blocks the IL-31 signaling pathway by combining with IL-31 receptor alphaIL-31 is an important cytokine that causes severe itchingGalderma recently presented its phase 2 findings on the treatment of patients with severe nodule itch at the(http:// conference of the 28th annualConference of the European Society of Dermatology and Stdilife.Compared to placebo, Nemolizumab not only met the main focus of thetrial(http:// , significantly improving the patient's peak itching numerical assessment scale (PP NRS) score, but also significantly improved skin lesions based on the researchers' Global Assessment (IGA) measurements Galderma is actively preparing to launch a critical Phase 3 clinical trial in 2020 to treat adult nodule itching with Nemolizumab
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
